

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(21) International Patent Classification 5: C12P 21/06, C12N 1/20, 1/12, A61N 63/00	A1	(21) International Publication Number: WO 94/19482
		(43) International Publication Date: 1 September 1994 (01.09.94)
(21) International Application Number: PCT/US94/01780	(21) Designated States: AU, CA, CN, JP, NZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, PT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 22 February 1994 (22.02.94)	Published with International search report.	
(46) Priority Data: US 08/20,501 22 February 1993 (22.02.93) US		
(71) Applicants: THE GENERAL HOSPITAL CORPORATION (USA); 180 Pilgrim Road, Boston, MA 02114 (US); THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (USA); 125 Quincy Street, Cambridge, MA 02138 (US).		
(72) Inventors: CALDERWOOD, Stephen, R.; 6 Pilgrim Road, Wellesley, MA 02181 (US); BUTTERKTON, John, R.; 46 Walnut Park, Newton, MA 02165 (US); MEXALANOS, John, J.; 478 Fresh Pond Lane, Cambridge, MA 02138 (US).		
(74) Agent: CLARK, Paul, T.; Fish and Richardson, 225 Franklin Street, Boston, MA 02110-2804 (US).		
(54) Title: HETEROLOGOUS ANTIGENS IN LIVE CELL VACCINE STRAINS		
(57) Abstract:		
<p>A bacterial cell (preferably a gram-negative, enteric bacterium such as <i>V. cholerae</i>) the chromosome of which contains a DNA sequence encoding a heterologous antigen, which sequence is functionally linked to an iron-regulated promoter such as the <i>trpA</i> promoter of <i>V. cholerae</i>.</p>		

BEST AVAILABLE COPY

5

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front page of pamphlets publishing international applications under the PCT.

AT	Annals	United Kingdom	Mauritius
AU	Australia	Canada	Niger
BR	Bolivia	China	Indonesia
DE	Belgium	Colombia	Iran
DK	Bulgaria	Congo	Iceland
ES	Bosnia and Herzegovina	Croatia	India
FI	Bulgaria	Cuba	Indonesia
FR	Burkina Faso	Egypt	Iran
GB	Burundi	El Salvador	Iraq
GR	Cambodia	Equatorial Guinea	Ireland
HK	Cameroon	Egypt	Italy
IL	Central African Republic	Emir of Kuwait	Jordan
IN	Chad	Guatemala	Kazakhstan
IS	Chile	Honduras	Korea, Rep.
JO	Colombia	Hungary	Kuwait
KR	Costa Rica	Indonesia	Lithuania
LT	Croatia	Iraq	Latvia
LU	Côte d'Ivoire	Iran	Lebanon
MD	Cuba	Iran, Islamic Rep.	Lithuania
MX	Djibouti	Iceland	Malta
NL	Egypt	Indonesia	Moldova
NO	Eritrea	Iran	Mongolia
PT	Egypt	Iran, Islamic Rep.	Montenegro
SE	Egypt	Iran, Islamic Rep.	Peru
SI	Egypt	Iran, Islamic Rep.	Romania
SK	Egypt	Iran, Islamic Rep.	Singapore
ZA	Egypt	Iran, Islamic Rep.	Sri Lanka
ZM	Egypt	Iran, Islamic Rep.	Tunisia
ZW	Egypt	Iran, Islamic Rep.	Viet Nam
AT	Annals	United Kingdom	Mauritius
AU	Australia	Canada	Niger
BR	Bolivia	China	Indonesia
DE	Bulgaria	Colombia	Iran
DK	Bulgaria	Cuba	India
ES	Burkina Faso	Equatorial Guinea	Iceland
FI	Bulgaria	Egypt	Indonesia
FR	Burundi	Emir of Kuwait	Iran
GB	Cambodia	Guatemala	Iran, Islamic Rep.
GR	Cameroon	Honduras	Kazakhstan
HK	Central African Republic	Hungary	Korea, Rep.
IL	Chad	Indonesia	Kuwait
IN	Chile	Iraq	Lithuania
IS	Colombia	Iran	Latvia
JO	Croatia	Iran, Islamic Rep.	Lebanon
KR	Côte d'Ivoire	Iran, Islamic Rep.	Lithuania
LT	Croatia	Iran, Islamic Rep.	Malta
LU	Djibouti	Iran, Islamic Rep.	Moldova
MD	Egypt	Iran, Islamic Rep.	Mongolia
MX	Egypt	Iran, Islamic Rep.	Montenegro
NL	Egypt	Iran, Islamic Rep.	Peru
NO	Egypt	Iran, Islamic Rep.	Romania
PT	Egypt	Iran, Islamic Rep.	Singapore
SE	Egypt	Iran, Islamic Rep.	Sri Lanka
SI	Egypt	Iran, Islamic Rep.	Tunisia
SK	Egypt	Iran, Islamic Rep.	Viet Nam
ZA	Egypt	Iran, Islamic Rep.	
ZM	Egypt	Iran, Islamic Rep.	
ZW	Egypt	Iran, Islamic Rep.	

- 1 -

HETEROLOGOUS ANTIGENS IN LIVE CELL VACCINE STRAINS

The field of the invention is genetically engineered live bacterial cell vaccine strains.

5 Statement as to Federally Sponsored Research
The work disclosed herein was supported in part by U.S. Public Health Service grant AI 27329 and a National Research Service Award from the National Institute of Allergy and Infectious Diseases.

10 Background of the Invention

V. cholerae is a gram-negative bacterium that causes a severe, dehydrating and occasionally fatal diarrhea in humans. There are an estimated 5.5 million cases of cholera each year, resulting in greater than 15 100,000 deaths (Bull. W.H.O. 68:1303-1312, 1990). Over the last several decades, cholera has been considered to occur primarily in developing countries of Asia and Africa, but recently it has reached epidemic proportions in regions of South and Central America, as well (Tauxe 20 et al., J. Am. Med. Assn. 267:1388-1390, 1992; Swardlow et al., J. Am. Med. Assn. 267:1495-1499, 1992).

Patients who recover from cholera infection have long-lasting, perhaps lifelong, immunity to reinfection (Levine et al., J. Infect. Dis. 143:818-820, 1981). The 25 development of *V. cholerae* vaccines has focused on reproducing this naturally occurring immunity, but the currently available parenteral, killed whole-cell vaccine preparation provides less than 50% protection from disease, for a duration of only 3 to 6 months (Saroso et 30 al., Bull. W.H.O. 56:619-627, 1978; Levine et al., Microbiol. Rev. 47:510-550, 1983). A genetically-engineered, live oral vaccine for *V. cholerae* has several theoretical advantages over the present parenteral killed whole-cell vaccine. As a mucosal pathogen, *V. cholerae*

- 2 -

adheres selectively to the M cells of the gastrointestinal tract (Owen et al., J. Infect. Dis. 153:1108-1118, 1986) and is a strong stimulus to the common mucosal immune system (Svennerholm et al., Lancet 5 i:305-308, 1982); and oral cholera vaccination in humans produces a strong salivary gland IgA response to cholera toxin B subunit (Czerkinsky et al., Infect. Immun. 59:1996-1991, 1991). Oral vaccines take advantage of the fact that oral administration of antigens appears to be 10 the most efficient stimulus for the development of secretory IgA (Svennerholm, *supra*), and that secretory IgA by itself is sufficient to protect against intestinal disease from *V. cholerae* (Winner III, et al., Infect. Immun. 59:977-982, 1991). Oral, killed whole cell 15 vaccines with or without the B subunit of cholera toxin have undergone extensive testing in volunteer and field trials over the past decade, and have been found to be more immunogenic and confer longer protection than the parenteral killed whole-cell vaccine (Svennerholm et al., 20 J. Infect. Dis. 149:884-893, 1984; Black et al., Infect. Immun. 55:1116-1120, 1987; Clemens et al., Lancet i:1375-1378, 1988; Clemens et al., J. Infect. Dis. 158:60-69, 1988; Järthorn et al., J. Infect. Dis. 157:374-377, 1988; Sack et al., 164:407-11, 1991).

25 Such killed whole-cell vaccines were traditionally favored over live whole-cell vaccines because the latter, which can multiply in the gut of the vaccinated animal, were considered unsafe. However, unlike killed-cell vaccines, live-cell vaccines would not require multiple doses, and in a rabbit model, live bacteria are more effective immunogens for secretory IgA than dead organisms (Keren et al., J. Immunol. 128:475-479, 1982). Live vaccines have the further advantage of potentially being transmitted from recipients to others in the 30 community, leading to herd immunity.

- 3 -

The most important virulence factor for *V. cholerae* in causing clinical disease is cholera toxin, a protein complex consisting of one A subunit and 5 B subunits. Live, oral vaccine strains currently being tested bear mutations in either the A subunit or in both subunits of cholera toxin (Mekalanos et al., *Nature* 306:551-557, 1983; Herrington et al., *J. Exp. Med.* 168:1487-1492, 1988; Levine et al., *Lancet* ii:467-470, 1988). An internal deletion of the gene encoding the A subunit of cholera toxin (*ctxA*) in the classical strain 0395 produces a strain (0395-N1) which is highly immunogenic in humans, but produces non-specific symptoms in about half of the recipients (Mekalanos, *supra*; Herrington, *supra*; Mekalanos, U.S. Patent No. 4,882,278, herein incorporated by reference), an indication that the strain is still virulent.

Summary of the Invention

As described in detail below, it has now been found that a *V. cholerae* gene, such as the *irgA* locus of *V. cholerae*, can function as a site for the integration and high-level expression of sequences encoding heterologous antigens in vaccine strains of *V. cholerae*. *IrgA*, the major iron-regulated outer membrane protein of *V. cholerae*, is a virulence factor for this organism that is independent of cholera toxin (Goldberg et al., USNN 07/629,102, herein incorporated by reference; Goldberg et al., *Infect. Immun.* 58:55-60, 1990). *In vivo*-grown *V. cholerae* expresses iron-regulated proteins that are not seen following growth in normal *in vitro* conditions (Sciortino et al., 42:990-996, 1983), suggesting that the organisms sense low-iron conditions in the intestine. A mutation in *irgA* produces a 100-fold defect in the virulence of *V. cholerae* in a suckling mouse model. Regulation of *irgA* expression by iron is

- 4 -

exceptionally tight, with a 1000-fold induction ratio in low- compared with high-iron conditions (Goldberg et al., *Infect. Immun.* 58:55-60, 1990). The entire structural gene of *irgA* has been cloned from the classical *V. cholerae* strain 0395 (Goldberg et al., *Mol. Microbiol.* 6:2407-2418, 1992). Use of such an iron-regulated promoter to control expression of a heterologous antigen in a live vaccine strain has a number of distinct advantages. A high induction ratio ensures that the gene encoding the heterologous antigen (1) will be expressed in the low-iron environment of the vaccinee's gut at a level high enough to ensure that it induces an immune response, and yet (2) will be expressed minimally when the cells are cultured *in vitro*, where high-level expression would potentially provide selection pressure favoring inactivation of the gene and complicate large-scale culturing of the cells necessary for vaccine production. Where, as in the case of *irgA*, the protein encoded by the naturally-occurring gene is, for at least some *V. cholerae* strains, a virulence factor that is not essential for growth of the bacterium, insertion of the heterologous antigen coding sequence next to the promoter can be readily accomplished in such a way as to delete or otherwise inactivate the virulence factor coding sequence, thereby decreasing the virulence of the engineered strain without affecting its viability.

The invention thus includes a genetically engineered *V. cholerae* chromosome containing a DNA sequence encoding a heterologous antigen, the DNA sequence being functionally linked to a naturally-occurring *V. cholerae* promoter. The heterologous antigen, defined as a polypeptide which is not expressed by the wildtype host species, is preferably a nontoxic polypeptide which is part or all of a protein that is naturally expressed by an infectious organism, and which

- 5 -

induces an antigenic response in an animal (preferably a mammal such as a human, non-human primate, cow, horse, sheep, goat, pig, dog, cat, rabbit, rat, mouse, guinea pig, or hamster). The infectious organism from which the heterologous antigen is derived may be, for example, a bacterium, a virus, or a eukaryotic parasite, and the heterologous antigen may be, e.g., an OSP (Outer Surface Protein) of *Shigella dysenteriae*; an immunogenic, nontoxic subunit or fragment of a bacterial toxin such as Shiga toxin, diphtheria toxin, *Pseudomonas* exotoxin A, pertussis toxin, tetanus toxin, anthrax toxin, one of the *E. coli* heat-labile toxins (LTs), one of the *E. coli* heat-stable toxins (STs), or one of the *E. coli* Shiga-like toxins; an immunogenic portion of a viral capsid 15 from a virus such as human immunodeficiency virus (HIV), any of the Herpes viruses (e.g., Herpes simplex virus or Epstein-Barr virus), influenza virus, poliomyelitis virus, measles virus, mumps virus, or rubella virus; or an immunogenic polypeptide derived from a eukaryotic 20 parasite, such as the causative agent for malaria, pneumocystis pneumonia, or toxoplasmosis. (One preferred example of such a polypeptide is a malarial circumsporozoite protein.) By "functionally linked to a naturally-occurring *V. cholerae* promoter" is meant that 25 expression of the sequence encoding the heterologous antigen is controlled by a promoter which is found in wild-type *V. cholerae*, such as the *ctxA* promoter, or an iron-regulated promoter such as that of *irgA*. Construction of such a functional linkage can be 30 accomplished as described in detail below, or generally, using standard methods, by locating the desired promoter sequence sufficiently near to (and typically, though not necessarily, just upstream of) the promoterless heterologous antigen-encoding sequence to permit the 35 desired promoter sequence to control expression of the

- 6 -

latter sequence. Functional siting of promoter sequences is well within the abilities of one of ordinary skill in the art of prokaryotic gene expression. Where the promoter naturally controls the expression of a *V. cholerae* virulence factor that is nonessential for growth of the cell, the sequence encoding that virulence factor will preferably be deleted or otherwise mutated to prevent expression of a biologically active form of that virulence factor. Preferably, the *ctxA* locus on the 10 chromosome will also be deleted or otherwise inactivated, so that biologically active cholera toxin cannot be expressed from the chromosome. Such deletions, mutations and insertions can readily be carried out by one of ordinary skill using the methods described herein, or 15 other well-known, standard techniques. In preferred embodiments, the *ctxA* deletion is identical to that of strain O395-N1 (Mekalanos, U.S. Patent No. 4,882,278).

Also within the invention is a bacterial chromosome (preferably from a gram-negative, enteric 20 bacterium such as *V. cholerae*), containing a DNA sequence encoding a heterologous antigen, which sequence is functionally linked to an iron-regulated promoter which functions in the host bacterium to permit significantly (i.e., at least ten-fold and preferably 100-fold) higher 25 expression of the heterologous antigen in a low-iron environment, such as in an animal's intestine, than in a high-iron environment, such as under typical *in vitro* culture conditions. An example of such a promoter is the naturally-occurring promoter of *V. cholerae* *irgA*, which 30 includes at a minimum a sequence substantially identical to nucleotides 1000 through 1041 (SEQ ID NO: 2), inclusive, of the sequence shown in Fig. 5 (SEQ ID NO: 1). The promoter sequence used is preferably nucleotides 922 to 1041 (SEQ ID NO: 3), more preferably 35 922 to 1079 (SEQ ID NO: 4) or 1000 to 1079 (SEQ ID

- 7 -

NO: 5), still more preferably 905 to 1041 (SEQ ID NO: 6) or 905 to 1079 (SEQ ID NO: 7), and most preferably 905 to 1438 (SEQ ID NO: 8), 922 to 1438 (SEQ ID NO: 9), or 1000 to 1438 (SEQ ID NO: 10) (all inclusive). Examples of 5 other iron-regulated promoters which would be useful in the invention are those derived from the *fate* gene of *V. anguillarum* (Koster et al., J. Biol. Chem. 266:23829-23833, 1991); *E. coli* *slt-IIA* (or other *E. coli* Fur-binding promoter sequences, as discussed by Calderwood et 10 al., J. Bacteriol. 169:4759-4764, 1987; De Grandis et al., J. Bacteriol. 169:4313-4319, 1987; and DeLorenzo et al., J. Bacteriol. 169:2624-2630, 1987); the iron-regulated outer membrane proteins of *Salmonella typhi* (Fernandez et al., Infect. Immun. 57:1271-1275, 1989), 15 the iron-regulated hemolysin promoter of *Serratia* (Poole et al., Infect. Immun. 56:2967-2971, 1988); the *Yersenia* iron-regulated promoters (Carniel et al., Molecular Microbiol. 6:379-388, 1992; Staggs et al., J. Bacteriol. 173:417-425, 1991; and Staggs et al., Molecular 20 Microbiol. 6:2507-2516, 1992); the *V. vulnificus* iron-regulated promoters; the *Pseudomonas* exotoxin A iron-regulated promoter (Bjorn et al., Infect. Immun. 19:785-791, 1978); and *Plesiomonas* iron-regulated genes involved in heme-iron uptake (Daskaleros et al., Infect. Immun. 25 59:2706-2711, 1991). It is believed that most if not all enteric, gram-negative bacterial species, including *E. coli*, *Salmonella*, *Shigella*, *Yersinia*, *Citrobacter*, *Enterobacter*, *Klebsiella*, *Morganella*, *Proteus*, *Providencia*, *Serratia*, *Vibrios*, *Plesiomonas*, and 30 *Aeromonas*, utilize highly similar fur-binding, iron-regulated promoter sequences, and it is likely that they also utilize secondary iron-regulated promoter sequences similar to that of *iryA*. Such promoter sequences are well-known to those of ordinary skill, or can be readily 35 determined from current information regarding iron-

- 8 -

regulated promoters. Construction of such promoter sequences adjacent to a given heterologous antigen-encoding sequence, and insertion of the resulting construct into a *V. cholerae* genome, is readily 5 accomplished by one of ordinary skill; the ability of such a promoter to function as predicted can then be tested in low- and high-iron conditions as described below, without undue experimentation.

Also within the invention is a *V. cholerae* cell, 10 or a homogeneous population of such cells, which contains the genetically engineered chromosome described above. Such cells can be said to define a vaccine strain useful, when combined with a pharmaceutically acceptable diluent suitable for oral administration, as a live-cell vaccine. 15 Administration of such a vaccine to an animal (e.g., a human or other mammal) will provoke immunity not only to *V. cholerae*, but also to an antigen derived from a second organism; it thus serves as a bivalent vaccine. An example of such a vaccine utilizes a genetically 20 engineered *V. cholerae* strain in which the *cctxA* and *iryA* coding sequences are largely deleted and a sequence encoding Shiga-like toxin B subunit is functionally linked to the *iryA* promoter. This strain is described in detail below. Of course, the bacterial strain of the 25 invention could be engineered to encode several heterologous antigens, each linked to an identical or different iron-regulated promoter, to produce a multivalent vaccine effective for simultaneously inducing immunity against a number of infectious diseases.

10 Other features and advantages will be apparent from the detailed description provided below, and from the claims.

- 9 -

Brief Description of the Drawings

Fig. 1 is a schematic diagram illustrating the construction of plasmids used in this study. A partial restriction map of O395 chromosomal DNA is shown with 5 relevant restriction enzyme sites, using base-pair numbering as in Goldberg et al., Mol. Microbiol. 6:2407-2418, 1992; and Goldberg et al., Proc. Natl. Acad. Sci. USA 88:1125-1129, 1991. The location of *irgA*, the location of fragments cloned in the construction of 10 vaccine strains and the locations of fragments used as probes in Southern blot analysis are indicated. The upstream *irgA* fragment is indicated by a solid bar; the downstream *irgA* fragment by a hatched bar; and the *slt-IB* subunit fragment by a stippled bar. Plasmids and 15 chromosomal fragments are not drawn to scale.

Figs. 2A-2B is a set of Southern blots illustrating hybridization of chromosomal DNA from wild-type and mutant *V. cholerae* strains, digested with *Hind*III, separated by agarose electrophoresis and probed 20 as follows: (A) *Sma*I - *Hinc*II fragment (region deleted in vaccine strains); (B) *Hinc*II - *Hinc*II fragment (downstream probe); (C) *Hind*III - *Sma*I fragment (upstream probe); (D) *Eco*RV - *Hind*III fragment from pSBC52 (*slt-IB* subunit probe). Lanes: 1, O395-N1; 2, SBC20; 3, B014-1; 25 4, B024-1; 5, VAC1; 6, VAC2; 7, O395-N1. The genomic location of the fragments used as probes is indicated in Fig. 1. The numbers to the left of the blot indicate the sizes (in kbp) of DNA standards.

Fig. 3 is a photograph of an SDS-PAGE analysis of 30 the outer membrane proteins expressed by certain *V. cholerae* strains when grown in high- or low-iron medium. Lanes: 1, O395-N1 grown in high-iron medium; 2, O395-N1 grown in low-iron medium; 3, SBC20 grown in low-iron medium; 4, VAC1 grown in low-iron medium; 5, VAC2 grown 35 in low-iron medium; 6, O395-N1 grown in low-iron medium.

- 10 -

The numbers to the left of the gel indicate the molecular masses (in kDa) of the protein standards.

Fig. 4 is a schematic diagram of the construction of the pSBC52 plasmid utilized in these experiments. 5 pSBC32 (Calderwood et al., Infect. Immun. 58:2977-2982, 1990) was subjected to PCR using primer No. 1: 5'-CCGAATTCTCTAGAGATATCGTGTGAAATTCTGACGCCATAA-3' (SEQ ID NO: 11), which introduces restriction sites for *Eco*RI, *Xba*I, and *Eco*RV, and primer No. 2: 10 5'-CCAAGCTTCTGCAGCCCCGGATTTAACATTATGAATCTCCGCCT-3' (SEQ ID NO: 12), which introduces restriction sites for *Hind*III, *Pst*I, and *Sma*I. The PCR product was then digested with *Eco*RI and *Hind*III, and cloned into *Eco*RI/*Hind*III-digested pUC19, to produce pSBC52. 15 Fig. 5 shows the nucleotide sequence of a portion of the *irgA* cDNA (SEQ ID NO: 1), including the promoter sequence. A 19-bp interrupted dyad symmetric element homologous to the *Fur* box of *E. coli* is indicated by inverted horizontal arrows below the sequence. Vertical 20 lines mark the margins of what is believed to be regions important for *irgA* promoter function.

Detailed Description

In the experiments described below, the non-toxic B subunit of Shiga toxin was used as a model heterologous 25 antigen, because of the easily available assays for this protein (Donohue-Rolfe et al., J. Clin. Microbiol. 24:65-68, 1986), as well as the possible role that antibodies against the B subunit play in protecting against severe Shigellosis and hemolytic uremic syndrome. Shiga toxin 30 is a heterodimeric protein consisting of one A subunit (MW 32 kDa) and five B subunits (MW 7.7 kDa) (Seidah et al., J. Biol. Chem. 261:13928-13931, 1986); the B subunit of Shiga toxin is identical in amino acid sequence to the B subunit of Shiga-like toxin I produced by

- 11 -

enterohemorrhagic strains of *E. coli* (Calderwood et al., Proc. Natl. Acad. Sci. USA 84:4364-4368, 1987). This identical protein product is referred to as Stx2 throughout this study. Immune response to Shiga toxin is primarily directed against the B subunit, and antibodies directed against this subunit, or against synthetic peptides from regions of the subunit, provide protective immunity against holotoxin (Donohue-Rolfe et al., J. Exp. Med. 160:1767-1781, 1984; Harari et al. Infect. Immun. 10 56:1618-1624, 1988; Harari et al., Mol. Immunol. 27:613-621, 1990; Boyd et al., Infect. Immun. 59:750-757, 1991).

Described below are the insertion of a promoterless gene for the Shiga-like toxin I B subunit (*slt*-IB) into an *iryA* deletion, and the introduction of this construct into the chromosome of the *V. cholerae* *ctxA* deletion strain O395-N1, thus producing a live, attenuated vaccine strain of *V. cholerae* that contains Stx2 under the transcriptional control of the iron-regulated *iryA* promoter.

20 MATERIALS AND METHODS

Bacterial strains and plasmids.

The bacterial strains and plasmids used in this study are described in Table 1, with the exception of plasmids pMBG126, pSAB18, pSAB12, pSAB19, pSAB14, and 25 pSAB24, which are described in detail below and are depicted in Fig. 1; and plasmid pSBC52, which is described in the description of Fig. 4 provided above. Standard plasmid cloning vectors pUC18, pUC19, and pBRJ22 are commercially available (e.g., Pharmacia).

30 Media.

All strains were maintained at -70°C in Luria broth (LB) media (Sambrook et al., A Laboratory Manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), containing 15% glycerol. LB media,

- 12 -

with or without the addition of the iron chelator 2,2-dipyridyl (final concentration, 0.2 mM), was used for growth in low- and high-iron conditions, respectively. Ampicillin (100 µg/ml), kanamycin (45 µg/ml), and 5 streptomycin (100 µg/ml) were added as appropriate. Genetic methods.

Isolation of plasmid and bacterial chromosomal DNA, restriction enzyme digests, agarose gel electrophoresis, and Southern hybridization of DNA 10 separated by electrophoresis were performed according to standard molecular biologic techniques (Sambrook, *supra*). GeneScreen Plus hybridization transfer membranes (DuPont Biotechnology Systems, NEN Research Products, Boston, MA) were used according to the manufacturer's protocols for 15 Southern hybridization. DNA sequencing was performed using the Sequenase DNA Sequencing Kit (United States Biochemical Corporation, Cleveland, OH).

Plasmids were transformed into *E. coli* strains by standard techniques, or were electroporated into *V. 20 cholerae* using a Gene Pulser (Bio-Rad Laboratories, Richmond, CA), following the manufacturer's protocol, and modified for electroporation into *V. cholerae* as previously described (Goldberg et al., Proc. Natl. Acad. Sci. USA 88:11225-11229, 1991). Electroporation conditions 25 were 2,500 V at 25-µF capacitance, producing time constants of 4.7-4.9 ms.

DNA restriction endonucleases, T₄ DNA ligase, calf intestinal alkaline phosphatase, and the Klenow fragment of DNA polymerase I were used according to the 30 manufacturers' specifications. Restriction enzyme-digested chromosomal and plasmid DNA fragments were separated on 1% agarose gels; required fragments were cut from the gel under ultraviolet illumination and purified by electroelution (Sambrook et al., 1989, *supra*). DNA 35 fragments used as probes were radiolabeled with α -³²P-dCTP

- 13 -

using a random priming labeling kit (Prime Time "C" Oligonucleotide Labeling Biosystem, International Biotechnologies, Inc., New Haven, CT).

Construction of plasmids.

5 DNA was recovered upstream and at the 5' terminus of *iryA* as a *Hind*III-*Sma*I fragment from pMBG59, which contains the *iryA* promoter (*iryP*) (Goldberg et al., J. Bacteriol. 172:6863-6870, 1990) (Fig. 1). This fragment was cloned into the *Hind*III and *Sph*I sites of pUC18 to 10 yield plasmid pMBG126; the *Sph*I site of pUC18 had first been made blunt-ended by treatment with mung bean nuclease. DNA sequence analysis of pMBG126 revealed that the *Sph*I site was unexpectedly preserved at the junction with *Sma*I; the sequence was otherwise as predicted. DNA 15 was then recovered at the 3' terminus and downstream of *iryA* as a 1.5 kilobase-pair (kbp) *Hinc*II fragment from plasmid pSAB25. *Sac*I linkers were added to this fragment and it was ligated into the unique *Sac*I site of pMBG126, in the same orientation as the upstream *iryA* fragment, to 20 yield plasmid pSAB18. The internal *Sai*I site in the pUC polylinker of pSAB18 was removed by digesting with *Sai*I, treating with the Klenow fragment of DNA polymerase I, and religating the blunt ends, to create pSAB12. A DNA segment encoding the promoterless B subunit of Shiga-like 25 toxin I (*sit-IB*) was recovered as an *Eco*RV-*Sma*I fragment from plasmid pSBC52. This fragment was introduced into the unique *Eco*RV and *Sma*I sites of pSAB18, such that *sit-IB* was under the transcriptional control of *iryP* on the upstream *iryA* fragment, yielding plasmid pSAB19. The 30 construction of plasmids pMBG126, pSAB18, pSAB12, and pSAB19 was verified by restriction enzyme digestion and double-stranded DNA sequencing.

The desired fragments were then introduced into the suicide vector pCVD442 as follows. pSAB12 and pSAB19 35 were digested with *Hind*III and *Eco*RI and the DNA fragment

- 14 -

containing either the *iryA* deletion (from pSAB12) or the *iryA* deletion-*sit-IB*-substitution (from pSAB19) were made blunt-ended by the Klenow fragment of DNA polymerase I. Following ligation to *Sai*I linkers, the fragments were 5 ligated into the unique *Sai*I site of pCVD442, yielding plasmids pSAB14 and pSAB24 respectively, and propagated in the permissive strain SM10 λ *pir*. Plasmid pCVD442 is a recently described suicide vector containing the *pir*-dependent R6K replicon, ampicillin resistance, and the 10 *sacB* gene from *Bacillus subtilis* (Donnenberg et al., Infect. Immun. 59:4310-4317, 1991).

Construction of VAC1 and VAC2

V. cholerae strain SBC20 is an *iryA*:TnphoA derivative of O395-N1 (Pearson et al., Res. Microbiol. 15 141:893-899, 1990). The kanamycin resistance marker in TnphoA allowed screening of mutants for deletion of *iryA* (and hence TnphoA) by assessing susceptibility to kanamycin. The *iryA* allele of SBC20 was replaced with either the previously constructed *iryA* deletion, or the 20 *iryA* deletion containing *sit-IB*, as follows. Plasmids pSAB14 and pSAB24 were electroporated into SBC20, with selection for ampicillin and streptomycin resistance. Doubly-resistant colonies contained the respective plasmids integrated into the chromosome by homologous 25 recombination involving either the upstream or downstream fragments of *iryA* on pSAB14 or pSAB24, with creation of a merodiploid state. One such colony from the integration of pSAB14 into the chromosome of SBC20 was selected and named BO14-1; one from the integration of pSAB24 into the 30 chromosome of SBC20 was named BO24-1. BO14-1 and BO24-1 were grown overnight in LB media without ampicillin selection, then plated on LB media with 10% sucrose but without NaCl, and grown at 30°C for 30 hours, thereby selecting for clones that had deleted the integrated *sacB* 35 gene (Blomfield et al., Mol. Microbiol. 5: 1447-1457,

- 15 -

1991). Sucrose-resistant colonies that are ampicillin susceptible but kanamycin resistant have re-excised the plasmid (yielding the parent SBC20, which contains the kanamycin resistance marker in TnphoA); those that are 5 both ampicillin and kanamycin susceptible have resolved the heterodiploid state to replace the *irgA* locus in SBC20 with either the *irgA* deletion from pSAB14 or the *irgA* deletion-sit-IB fragment from pSAB24. Approximately 10^t of sucrose-resistant colonies that were ampicillin-10 susceptible were also kanamycin-susceptible. One of these colonies which had replaced the *irgA*:TnphoA locus with the *irgA* deletion was further purified and named VAC1; one which had replaced the *irgA*:TnphoA locus with *irgA*:*irgP*-sit-IB was named VAC2. Confirmation of the 15 proper constructions in VAC1 and VAC2 was obtained by Southern hybridization of restriction enzyme-digested chromosomal DNA that was probed with several different DNA fragments to verify the expected deletion in *irgA*, as well as the introduction of the sit-IB within the deleted 20 *irgA* segment.

Preparation of outer-membrane proteins, whole cell proteins, and periplasmic extracts.

Enriched outer membrane proteins were prepared from strains following growth in low- and high-iron media 25 as previously described (Goldberg, Infect. Immun. 58:55-60, 1990). Proteins were separated by electrophoresis on a sodium dodecyl sulfate/10% polyacrylamide (SDS-PAGE) gel and visualized by staining with Coomassie brilliant blue. Whole cell proteins and periplasmic extracts were 30 prepared from exponentially growing cells as previously described (Hovde et al., Proc. Natl. Acad. Sci. USA 85:2568-2572, 1988).

Immunodetection of StxB production.

Whole cell proteins and periplasmic extracts were 35 separated on a SDS-15% PAGE gel as described above, then

- 16 -

transferred to a NitroBind Transfer Membrane (Micron Separations Inc., Westboro, MA) with a semidry blotting apparatus (Hoefer Scientific Instruments, San Francisco, CA). Immunoreactive proteins were visualized after 5 sequential incubation with polyclonal rabbit anti-Shiga toxin antiserum and goat anti-rabbit IgG-conjugated alkaline phosphatase (Sigma Chemical Co., St. Louis, MO), followed by staining for phosphatase activity as described previously (Hovde, *supra*). The amount of StxB 10 present in periplasmic extracts or culture supernatants was quantitated with an enzyme-linked immunosorbent assay (ELISA) developed for the detection of Shiga toxin and modified for detection of purified StxB (Donchua-Rolfe et al., J. Clin. Microbiol. 24:65-68, 1986; Calderwood et al., Infect. Immun. 58:2977-2982, 1990).

HeLa cell cytotoxicity.

The cytotoxicity of periplasmic extracts or culture supernatants for HeLa cells was assayed in a quantitative cytotoxicity assay by determining the extent 20 of HeLa cell detachment from microtiter plates (Gentry et al., J. Clin. Microbiol. 12:361-366, 1980). HeLa cells were grown at 37°C in a 5% CO₂ atmosphere in McCoy 5A (modified) medium containing 10% fetal calf serum and 100 µg of penicillin and streptomycin per ml. Freshly 25 trypsinized cells were suspended in 0.1 ml of growth medium and allowed to attach to the wells of microtiter plates overnight. Serial dilutions of samples were added and the plates were again incubated overnight. The cells were fixed and then stained with crystal violet in a 5% ethanol - 2% formaldehyde solution. Stained cell monolayers were dissolved in ethanol and the A₅₉₅ read with a microtiter plate colorimeter.

Evaluation of virulence of vaccine strains.

50^t lethal dose (LD₅₀) assays were performed by 35 oral inoculation of 3- to 4-day old CD1 suckling mice

- 17 -

with either the parent *V. cholerae* strain 0395, an *irgA* mutant strain MBG40 (Goldberg et al., *Infect. Immun.* 58:55-60, 1990), the *ctxA* mutant strain 0395-N1, or VAC2. Cholera strains were grown overnight in LB medium at 5 30°C, pelleted, and resuspended in 0.5M NaHCO₃ (pH 8.5). Mice were orally inoculated with serial dilutions of organisms, then kept at 30°C. Four or more mice were used per dose of bacteria. Survival was determined at 10 40 h (Taylor et al., *Proc. Natl. Acad. Sci. USA* 84:2833-2837, 1987).

RESULTS

Confirmation of vaccine strain construction.

(i) Southern hybridization analysis. To confirm the construction of the vaccine strains, chromosomal DNA 15 was purified from *V. cholerae* parent strains 0395-N1 and SBC20, the merodiploid strains BO14-1 and BO24-1, and the vaccine strains VAC1 and VAC2. The chromosomal DNAs were digested with *Hind*III, separated on agarose gels, and transferred to membranes for Southern hybridizations. 20 The Southern hybridizations of these digests, probed with four different fragment probes, are shown in Fig. 2. The location of the fragment probes within the *irgA* gene is shown in Fig. 1. The presence and size of the recognized fragments is consistent with the constructions depicted 25 in Fig. 1, confirming the deletion of *irgA* in VAC1 and the deletion-replacement of the *irgA* locus with *irgA::irgP-sltIB* in VAC2.

ii. Outer membrane protein analysis. Outer membrane proteins were prepared from strain 0395-N1 grown 30 in low- and high-iron media and from strains SBC20, VAC1 and VAC2 following growth in low-iron media, then separated by electrophoresis on a SDS-PAGE gel (Fig. 3). IrgA, the 77 kilodalton (kDa) major iron-regulated outer membrane protein (Goldberg et al., *Infect. Immun.* 58:55-60, 1990), is present in 0395-N1 grown in low iron but is 35

- 18 -

absent in SBC20 (an *irgA* mutant) and the vaccine strains, confirming the deletion of *irgA* in VAC1 and VAC2. Iron-regulated expression of the Shiga toxin B subunit in VAC2.

5 (i) Western blot analysis of StxB production in VAC2. Western blot analysis of whole cell proteins and periplasmic extracts of VAC2 grown in high- and low-iron media demonstrated the production of a 7.7 kDa protein recognized by polyclonal rabbit anti-Shiga toxin 10 antiserum in both whole cell proteins and periplasmic extracts prepared from VAC2 grown in low-iron media; no such protein was recognized in proteins prepared from the vaccine strain grown in high-iron media, demonstrating that the production of StxB is tightly iron-regulated. 15 (data not shown).

(ii) Quantitation of StxB production from irgP-sltIB in plasmid pSAB19 and VAC2. To verify iron-regulated production of StxB by *irgP-sltIB* in plasmid pSAB19, and compare it with StxB production by VAC2, we 20 first had to return pSAB19 to the *V. cholerae* background because *irgP* is not active in *E. coli* (Goldberg et al., *Proc. Natl. Acad. Sci. USA* 88:1125-1129, 1991). The production of StxB by strains 0395-N1(pSAB19) and VAC2 was quantitated using a sandwich ELISA, with a monoclonal 25 antibody specific for StxB as the capture molecule. Purified StxB, in measured amounts, was used as the standard. As shown in Table 2, both 0395-N1(pSAB19) and VAC2 express StxB in a tightly iron-regulated fashion, as expected, and produce five times the amount of B subunit, 30 made by the reference strain, *Shigella dysenteriae* 50R, under low-iron conditions.

Virulence of vaccine strains.

(i) Cytotoxicity to HeLa cells. The cytotoxicity of periplasmic extracts or culture supernatants of 35 strains 0395-N1(pSAB19) and VAC2, grown in low-iron

- 19 -

media, was assayed as described (Gentry et al., J. Clin. Microbiol. 12:361-366, 1980), and compared to the *S. dysenteriae* strain 60R. Neither 0395-N1(pSAB19) or VAC2 had detectable cytotoxicity in periplasmic extracts or supernatants, in contrast to periplasmic extracts of *S. dysenteriae* 60R, which were cytotoxic to at least a 10³-fold dilution (data not shown).

(ii) LD₅₀ assays. The results of LD₅₀ assays for the wild-type *V. cholerae* strain 0395, ctxA mutant strain 0395-N1, irgA mutant strain MBG40, and vaccine strain VAC2 in the suckling mouse model are shown in Table 3. *V. cholerae* strain MBG40, an irgA::TnphoA mutant of strain 0395, had an LD₅₀ in suckling mice that was 2 orders of magnitude higher than that for the parental strain 0395, as previously demonstrated (Goldberg et al., Infect. Immun. 58:55-60, 1990). Strain 0395-N1, deleted for the A subunit of cholera toxin, was avirulent at an inoculum of 2 × 10⁹ organisms in this model. The vaccine strain VAC2, despite expressing StxB at high level, remains avirulent in this model at an inoculum of 2 × 10⁹ organisms, similar to its parent strain 0395-N1.

USE

The *V. cholerae* strains of the invention are useful as bivalent vaccines capable of inducing immunity to *V. cholerae* and to an antigen derived from a second infectious organism. Because the strains are attenuated (i.e., do not induce a significant toxic reaction in the vaccinee), they can be used as live-cell vaccines, permitting effective immunity to result from administration of a single dose of the vaccine. An effective oral dose of the vaccine would contain approximately 10⁶ to 10⁸ bacteria in a volume of approximately 150 ml liquid. The diluent used would typically be water or an aqueous solution, such as

- 20 -

2 grams of sodium bicarbonate dissolved in 150 ml distilled water, which may be ingested by the vaccinee at one sitting, either all at once or over any convenient period of time.

5

Other Embodiments

Other embodiments are within the claims set forth below. For example, the host bacterium (the bacterium the chromosome of which is engineered to encode a heterologous antigen) can be *E. coli* or any other enteric bacterium, including *Salmonella*, *Shigella*, *Yersinia*, *Citrobacter*, *Enterobacter*, *Klebsiella*, *Morganella*, *Proteus*, *Providencia*, *Serratia*, *Plesiomonas*, and *Aeromonas*, all of which are known or believed to have iron-regulated promoters similar to the Fur-binding promoters of *E. coli*, and which may have other iron-regulated promoters analogous to that of irgA. Also potentially useful would be a bacille Calmette-Guérin (BCG) vaccine strain engineered to encode a heterologous antigen linked to an iron-regulated promoter. The promoter used can be native to the species of the host bacterium, or can be a heterologous promoter (i.e., from a species other than that of the host bacterium) engineered into the host bacterium along with the heterologous antigen coding sequence, using standard genetic engineering techniques. Multiple heterologous antigen coding sequences linked to the same or different iron-regulated promoter sequences can be inserted into a given chromosome, using techniques analogous to those set forth above, to produce a multivalent vaccine strain.

30 Those who practice in the field of prokaryotic gene expression will realize that, while naturally-occurring promoter sequences are preferred, synthetic sequences such as a consensus Fur-binding sequence or a hybrid of two or more Fur-binding sequences would also be

- 21 -

expected to be useful in the chromosomes of the invention. Alteration, addition or deletion of one or a few nucleotides within a naturally-occurring promoter sequence such as the *irgA* promoter would generally not affect its usefulness. The invention therefore encompasses iron regulated promoters having such inconsequential changes.

- 22 -

Table I. Bacterial strains and plasmids used in this study

	Strain or plasmid	Relevant genotype or phenotype	Ref. or source
5	<i>V. cholerae</i> strains		
	O395	<i>Sm'</i>	1
	O395-M1	O395 <i>cctxA</i> , <i>Sm'</i>	1
	SBC20	O395-M1 <i>irgA1::TnphoA</i> , <i>Sm'</i> , <i>Xm'</i>	2
	NB640	O395 <i>irgA1::TnphoA</i> , <i>Sm'</i> , <i>Km'</i>	3
10	B014-1	SBC20 with pSAB14 integrated into <i>irgA</i> , <i>Sm'</i> , <i>Km'</i> , <i>Ap'</i>	4
	B024-1	SBC20 with pSAB24 integrated into <i>irgA</i> , <i>Sm'</i> , <i>Km'</i> , <i>Ap'</i>	4
	VAC1	O395-M1 <i>irgA</i> , <i>Sm'</i>	4
15	VAC2	O395-M1 <i>irgA1::irgF-sic-IB</i> , <i>Sm'</i>	4
	<i>E. coli</i> strains		
	SM10 λ <i>pir</i>	<i>thi</i> <i>thr</i> <i>leu</i> <i>cba</i> <i>lacZ</i> <i>supE</i> <i>recA1::RP4-2-Tc::Mu λ pirR6K</i> , <i>Km'</i>	5
	Plasmids		
20	pNBG59	pBR322 with 4.7-kbp of <i>V. cholerae</i> NB640 chromosome, containing DNA upstream and at the 5' terminus of <i>irgA</i> , as well as the <i>irgA1::TnphoA</i> fusion joint from this strain.	6
25	pSAB25	1.0 kbp <i>Smal</i> - <i>MluI</i> fragment of <i>V. cholerae</i> O395 chromosome, containing DNA at the 3' terminus and downstream of <i>irgA</i> , made blunt-ended at the <i>MluI</i> site and ligated into <i>Smal</i> -digested pOC19.	4
30	pSBC52	pOC19 with a promoterless gene for the B subunit of <i>SLT-I</i> (identical to <i>StxB</i>) cloned between the <i>EcoRI</i> and <i>HindIII</i> sites.	4
35	pCVD442	Suicide vector composed of the <i>sob</i> , <i>ori</i> , and <i>bla</i> regions from pCF704 and the <i>sacB</i> gene of <i>Sacillus subtilis</i> .	7
40		<i>Ap'</i> , ampicillin resistance; <i>Km'</i> , kanamycin resistance; <i>Sm'</i> , streptomycin resistance.	

- 23 -

Ref. or source:

- 5
1. Makalanski et al., Nature 306:551-557, 1983.
 2. Pearson et al., Res. Microbiol. 141:893-899, 1990.
 3. Goldberg et al., Infect. Immun. 58:55-60, 1990.
 4. This study.
 5. Miller et al., J. Bacteriol. 170:2575-2583, 1988.
 6. Goldberg et al., J. bacteriol. 172:6863-6870, 1990.
 7. Donnenberg and Kaper, Infect. Immun. 59:4310-4317, 1991.

- 24 -

Table 2. Production of Shiga toxin B subunit by various strains following growth in high- and low-iron conditions

Strain	Periplasmic extract ^a		Supernatant ^a	
	High-iron	Low-iron	High-iron	Low-iron
iron				
O395-M1	— ^b	—	—	—
O395-M1 (pSAB19)	15.5	3,620	0.16	3.5
VAC2	0.87	4,130	—	0.73
<i>E. dysenteriae</i> 60R	238	674	0.8	16.4

^a ng/50 OD₆₀₀ of original culture^b < 0.1 ng

- 25 -

Table 3. Virulence assays of wild-type and mutant strains of *Vibrio cholerae* in suckling mice

	Strain	LD ₅₀ (no. of bacteria)
5	O395	1 x 10 ⁵
	MDC40	1 x 10 ⁷
	O395-M1	> 2 x 10 ⁹
10	VAC2	> 2 x 10 ⁹

- 26 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Calderwood, Stephen B.
Butterton, Joan R.
Makalambas, John J.
- (ii) TITLE OF INVENTION: HETEROLOGOUS ANTIGENS IN LIVE CELL VACCINE STRAINS
- (iii) NUMBER OF SEQUENCES: 12
- (iv) CORRESPONDENCE ADDRESS:
- (A) ADDRESSEE: Fish & Richardson
(B) STREET: 225 Franklin Street
(C) CITY: Boston
(D) STATE: Massachusetts
(E) COUNTRY: U.S.A.
(F) ZIP: 02110-2804

(v) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: 3.5" Diskette, 1.44 MB
(B) COMPUTER: IBM PS/2 Model 50X or 55SX
(C) OPERATING SYSTEM: MS-DOS (Version 5.0)
(D) SOFTWARE: WordPerfect (Version 5.1)

(vi) CURRENT APPLICATION DATA:

- (A) APPLICATION NUMBER: 08/020,501
(B) FILING DATE: February 23, 1993
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER:
(B) FILING DATE:

(viii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: Clark, Paul T.
(B) REGISTRATION NUMBER: 30,162
(C) REFERENCE/DOCKET NUMBER: 00786/136001

(ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: (617) 542-5070
(B) TELEFAX: (617) 542-8906
(C) E-MAIL: 200154

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1535
(B) TYPE: nucleic acid
(C) STRANDEDNESS: both
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

- 27 -

ATCGATGATA	AAAAATCCCG	CTGGCGCGGG	AATTTCAT	GCCACTCATC	GGGCCTTGT	60
TOGGGGAGG	CATCAATAAA	TAGGCCGACG	CGAAGTGCGG	GACGACCGAG	CGATGAGAAG	120
CACTGATT	CTGTTGGCTG	TGATTCUCA	CGCTTAACCC	ACGAATGAG	CTGGCGCGGA	180
TCCCCCGTT	CAAAACCA	GCGAACCAA	CTGGGAGAGG	ACCAATACG	ACGUACCTTA	240
GCAATGUCAT	GGGCTTGAT	GGCAGAGATA	TGGCTTGTG	ACGACTCTG	TAGTCGCTGC	300
ATGAAATAAC	TGGCGAACTC	TGAGATGTC	AGTCAGAGCT	CGCGCGCGG	ACAGGCGATA	360
AAATCAATCC	ATGGGTGAT	ATTCAGCTCA	CGAGGATGCG	TGGCTTGTG	TGAGATGGCC	420
AAATATTGCG	AGAGGGCGTA	ATGCGATAC	CGCGATAGCG	CTAGCGCTC	TTTGCGATTA	480
CCCATGGGG	CGCGGTGTC	AAATCCAATG	ATCAATCGG	GTCAGAACAC	CTCATCACTG	540
TGTTGAACT	GGCTGACTAC	ACGGATCTTC	ATATTCGAA	GCTCTGCGAT	AAATCTCATCC	600
AAATCTGGC	TGAGCCACCC	GGGGATCAA	TGGGGGTGCA	CCACGACGCG	GAGTCGCGCA	660
CTCACCTGAT	TGACGACGCG	GGGGATCAA	TGGGGGTGCA	CCACGACGCG	GAGTCGCGCA	720
TGCTCCGAGT	AAACCCGAA	CACTTCCTC	CTTTCGTTG	GCTTTCAGG	TTTCCTGTA	780
CUCATCAACA	AGCTTTCG	CAAGTCCTC	TCAGTTGCG	CCACGACGCG	ACTCAGGCG	840
GATTAGGGT	GTTCAGCGC	TTCGGCGACG	GCAGTCAGCG	TCTTATGTTG	GCAGAGCGCA	900
TGAAAGCTT	TTACGGCGCT	GAGATCTTCG	ATAGGTATTC	GACCTTTAAC	GAATAATATAC	960
CACAGACGTT	CCATATTG	ACCGAACATAT	TCCATGTC	CTACGATCTC	CACTACAGAA	1020
TATATGATA	ATCCCGCTCT	GAATTAAGA	ATATTTATCA	TTTAAAGGAA	TGTTAA	1076
ATG TCC AAG TTC ATT CCA TCC CCC GTC AGT TTA TCT GTG ACA CTA CGC	Met Ser Arg Phe Asn Pro Ser Pro Val Ser Leu Ser Thr Leu Gly	1124				
5 10 15						
TTA ATC TTT TCC CCT ACC CCT TTT CCT CAA GAC CGG ACC AAA ACG CAT	Leu Met Ser Gln Ser Ala Ser Ala Phe Ala Glu Asp Ala Thr Lys Thr Asp	1172				
20 25 30						
GAA ACC ATG GTG GTC ACT CGG CGG CGA TAC CGG CAA GTC ATT CGA AAT	Glu Thr Met Val Val Thr Ala Ala Gly Tyr Ala Glu Val Ile Glu Asn	1220				
35 40 45						
GCA CCA GCC ACT ATC ATG GTG ATT TCA AAG GAA GAT CTC GAA TCT CGC	Ala Pro Ala Ser Ile Ser Val Ile Ser Arg Glu Leu Glu Ser Arg	1268				
50 55 60						
TAT TAC CCT GAT GTG ACC GAT CGG CTA AAA ACC GTC CGG GCT CTC ACA	Tyr Tyr Arg Asp Val Thr Asp Ala Leu Lys Ser Val Pro Gly Val Thr	1316				
65 70 75 80						
GTC ACC GGA GGG GGC GAT ACT ACC GAT ATC ACG ATT CCT GCT GGT ATG CGA	Val Thr Gly Gly Asp Thr Asp Ile Ser Ile Arg Gly Met Gly	1364				
85 90 95						
TCA AAC TAT ACT CCT ATC TTC GTG GAT GGT AGG CGC CAA ACC TCA CGC	Ser Asn Tyr The Leu Ile Leu Val Asp Gly Lys Arg Thr Ser Arg	1412				
100 105 110						

- 28 -

CAG ACC CCT CCA AAC ACC GAT CGG CGG CGG ATT GAG CAA GGT TGG TTA		1460
Gln Thr Arg Pro Asn Ser Asp Glu Pro Gly Ile Glu Glu Gly Trp Leu	115 120 125	
CGG CCA CTG CAA CGG ATT GAA CCT ATC GAG GTG ATC CCT GGC CGG ATG		1508
Pro Pro Leu Glu Ala Ile Glu Arg Ile Glu Val Ile Arg Gly Pro Met	130 135 140	
TCT ACC CTC TAC CGC TCC GAT GCT GAC		1535
Ser Thr Leu Tyr Gly Ser Asp Ala Asp	145 150	

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 81
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

TCCATGTCG CAGCTATCTC CAGTACAGAA TATATGATAA ATCCCGCTCT G 51

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 120
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

AGATCTTCCA TAGCTTATTC ACCCTTAAAG ATATAATTAC ACACAGCGTC CATAATTGGA 60
CCGAACTTATT CCATGTGTCG ATCTATCTCC AGTACAGAAT ATATGATAA TCCGCTCTG 120

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 158
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

AGATCTTCCA TAGCTTATTC ACCCTTAAAG ATATAATTAC ACACAGCGTC CATAATTGGA 60
CCGAACTTATT CCATGTGTCG ATCTATCTCC AGTACAGAAT ATATGATAA TCCGCTCTG 120
AAATTGAA TAATTATCAT TTAAAGGAGT GCTAAAT 158

- 29 -

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 80
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: both
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

CGATCTATCT CCAAGTACAGA ATATATGAA AATCCGCCTC TGAATTAAAG AATAATTATC	60
ATTTAAAGGA GTGGTAAATG	80

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 137
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: both
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

AAGCTTTAAC GGGCGTGAGA TCTTGCATAG GTATTTCGCC CTTAAGAAAT AATTACCA	60
GACGTTCAT ATTGGACCC AACTATTCGA TGTGTGCGATC TATCTCCAGT ACAGAAATA	120
TGAATAATCC CCTCTTCAA TTAACTTAA TTAACATTTA AAGGAGTGT AAATGTTCCAG	137

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 175
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: both
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

AAGCTTTAAC GGGCGTGAGA TCTTGCATAG GTATTTCGCC CTTAAGAAAT AATTACCA	60
GACGTTCAT ATTGGACCC AACTATTCGA TGTGTGCGATC TATCTCCAGT ACAGAAATA	120
TGAATAATCC CCTCTTCAA TTAACTTAA TTAACATTTA AAGGAGTGT AAATGTTCCAG	175

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 534
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: both
 (D) TOPOLOGY: linear

- 30 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

AAGCTTTAAC GGGCGTGAGA TCTTGCATAG GTATTTCGCC CTTAAGAAAT AATTACCA	60
GACGTTCAT ATTGGACCC AACTATTCGA TGTGTGCGATC TATCTCCAGT ACAGAAATA	120
TGAATAATCC CCTCTTCAA TTAACTTAA TTAACATTTA AAGGAGTGT AAATGTTCCAG	180
ATTCAATCCA TCCCCCGTCGA GTTTATCTGT GACACTAGGC TTATGTGTTT CGGCTAGCGC	240
TTTTCCTCAA GACCCCAACCA AARCCCATCA AACCCTGTCG GTCACTGGG CGGGATACCG	300
GCAACTGTTT CAAATGCGC CAACGGATCT CACTGTGTT TCAAGGAAAT ATCTGGATTC	360
TCGCTTAACTC CGTGTGCTCA CGGATGCGCT AAAAGGCGTA CGGGGTGTTA CAGTCACCGG	420
ACGGGGCGAT ACTACCCCTAA TCAGCAATTG TGCTTATGGA TCAAAACTATA CTCTTATCTT	480
GTCGCGATGT AAGCCCGAAA CCTCAACCCCA GACCCCGTCGA AACACGGATG CGCC	534

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 517
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: both
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

AGATCTTGGG TGGGTTATTG ACCCTTAAAG AATATTTACG ACAGACGTTT CATAATTTGGA	60
CCGAATTAATCTT CCATGTCTGG ATCTTATCTCC ACTACAGATG ATATGAAATA TCCCTCTCTG	120
AAATTAAGAA TAATTTATCAT TTAAAGGAGT GTTAAATGTC CAGATTCAAT CCATCCCCCG	180
TCACTTATTC TCTCACACTA CGCTTAACTGT TTTCGGCTCA COCTTTGCTG CAAACGCGGA	240
CGAAACCGGA CGAAACCATC GTGGTCACTGA CGCGCGGATG CGCGCAAGTC ATTCACAAATG	300
CACCAACCCAT TATCACTGTT ATTTCAAGAG AGAGATCTGA ATCTGGCTAT TACCGTGTG	360
TGACCGATGC GCTAAACAGC GTACCGGGTC TGACACTCAC CGGAGGGGGC GATACTACCG	420
ATATCAGCAT TGTGGTGTATG GGATCAAATC ATATCTTCTAT CTGGTGGAT GGTAAAGGCC	480
AAACCTCAAC CGACACCGCTT CCAACACGGG ATGGGCC	517

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 439
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: both
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

- 31 -

CGAGCTATCT CCAAGTACAGA ATATAATGAA TAYCCGGCTTC TGAAATTAGG AATAATTATC
 ATTAAACGA GTGGTAAAGG TCCAGATTCA ATCCATCCCC CTCAGTTTA TGTGTGACAC 60
 TAGCTCTTAT GTTTCGCGCT ACCGGCTTTTG CTCTAGACCC GACCAAACCG GATGAAACCA 120
 TGGTGGTCAAC TCCGGCGGG TACGCCGAG TGATTCAAAA TGTCTCCGGCT AGTATCAGG 180
 TGATTTCAGG ACAGAGATCTG GAATCTCGT ATTACCGTGA TGTGACCGAT GGCTTAAAAA 240
 GCGTACCGGG TGTGACCGT ACCCGGAGGGG GCGTATCTAC CGATATCAGC ATTCGCGTA 300
 TGGCATCAA CTATACCTT ATCTTGCTGG ATGCTTAAGGC CGAACCTCA CGCCGAGGCC 360
 GTCGAAACAGCG CGATGCCCG 420
 439

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 42
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

CCGAAATTCTC TAGAGATATC GTGTGGAATT GTGAGCGGGAT AA 42

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 45
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

CCAGCTCTT CGACCCGGGG ATTAAACAT TATGAAATCTC CGCGT 45

- 32 -

CLAIMS

1. A bacterial chromosome containing a DNA sequence encoding a heterologous antigen, said DNA sequence being functionally linked to an iron-regulated promoter.
- 5 2. The chromosome of claim 1, wherein said chromosome is a *Vibrio cholerae* chromosome.
- 10 3. The chromosome of claim 1, wherein said chromosome is a chromosome of an *E. coli* bacterium, a *Shigella* bacterium, a *Salmonella* bacterium, a *Yersinia* bacterium, a *Citrobacter* bacterium, an *Enterobacter* bacterium, a *Klebsiella* bacterium, a *Proteus* bacterium, a *Providencia* bacterium, a *Serratia* bacterium, a *Vibrio* bacterium, a *Plesiomonas* bacterium, an *Aeromonas* bacterium, or a bacille Calmette-Guerin (BCG).
- 15 4. The chromosome of claim 1, wherein said promoter is the promoter of a naturally-occurring *V. cholerae* gene.
- 20 5. The chromosome of claim 4, wherein said promoter is the *V. cholerae* *irgA* promoter, and said chromosome lacks part or all of the *irgA* coding sequence.
- 25 6. The chromosome of claim 5, wherein said promoter comprises a nucleotide sequence substantially identical to SEQ ID NO: 2.
7. The chromosome of claim 1, wherein said heterologous antigen is a nontoxic polypeptide which induces an antigenic response in an animal.

- 33 -

8. The chromosome of claim 7, wherein said polypeptide is a portion or all of a protein naturally expressed by an infectious organism.

9. The chromosome of claim 8, wherein said infectious organism is a bacterium.

10. The chromosome of claim 9, wherein said polypeptide is an immunogenic, nontoxic subunit or fragment of a bacterial toxin.

11. The chromosome of claim 10, wherein said 10 toxin is Shiga toxin, diphtheria toxin, *Pseudomonas* exotoxin A, cholera toxin, pertussis toxin, tetanus toxin, anthrax toxin, *E. coli* heat-labile toxin (LT), *E. coli* heat-stable toxin (ST), or *E. coli* Shiga-like toxin.

12. The chromosome of claim 9, wherein said 15 protein is an OSP (Outer Surface Protein) of *Borrelia burgdorferi*.

13. The chromosome of claim 8, wherein said infectious organism is a virus and said polypeptide is an immunogenic portion of a viral capsid.

20 14. The chromosome of claim 13, wherein said virus is a human immunodeficiency virus (HIV), one of the Herpes viruses, an influenza virus, a poliomyelitis virus, a measles virus, a mumps virus, or a rubella virus.

25 15. The chromosome of claim 8, wherein said infectious organism is a eukaryotic parasite.

- 34 -

16. The chromosome of claim 15, wherein said parasite is the causative agent for malaria, pneumocystis pneumonia, or toxoplasmosis.

17. The chromosome of claim 16, wherein said 5 protein is a malarial circumsporozoite protein.

18. The chromosome of claim 2, wherein said chromosome does not encode biologically active cholera toxin A subunit.

19. The chromosome of claim 5, wherein said 10 chromosome does not encode biologically active cholera toxin A subunit.

20. A *V. cholerae* chromosome containing a DNA sequence encoding a heterologous antigen, said DNA sequence being functionally linked to a naturally- 15 occurring *V. cholerae* promoter.

21. The chromosome of claim 20, wherein said promoter is the promoter of a naturally-occurring gene encoding a *V. cholerae* virulence factor that is nonessential for growth of said cell, the coding sequence 20 encoding said virulence factor being mutated or deleted so that said chromosome cannot express a biologically active form of said virulence factor.

22. The chromosome of claim 20, wherein said promoter is the *iryA* promoter.

25 23. The chromosome of claim 20, wherein said heterologous antigen is part or all of a nontoxic polypeptide which is naturally expressed by an infectious

- 35 -

organism, which antigen induces an antigenic response in an animal.

24. The chromosome of claim 23, wherein said infectious organism is a bacterium.

5 25. The chromosome of claim 24, wherein said antigen is an immunogenic, nontoxic subunit or fragment of a bacterial toxin.

10 26. The chromosome of claim 25, wherein said toxin is Shiga toxin, diphtheria toxin, *Pseudomonas* exotoxin A, cholera toxin, pertussis toxin, tetanus toxin, anthrax toxin, *E. coli* LT, *E. coli* ST, or *E. coli* Shiga-like toxin.

15 27. The chromosome of claim 23, wherein said infectious organism is a virus and said antigen is an immunogenic portion of a viral capsid.

20 28. The chromosome of claim 27, wherein said virus is a human immunodeficiency virus (HIV), one of the Herpes viruses, an influenza virus, a poliomyelitis virus, a measles virus, a mumps virus, or a rubella virus.

25 29. The chromosome of claim 23, wherein said infectious organism is a eukaryotic parasite.

30. The chromosome of claim 29, wherein said parasite is the causative agent for malaria, pneumocystis pneumonia, or toxoplasmosis.

- 36 -

31. The chromosome of claim 20, wherein said chromosome does not encode biologically active cholera toxin A subunit.

5 32. A *V. cholerae* cell, the chromosome of which is the chromosome of claim 1.

33. A *V. cholerae* strain, the chromosome of which is the chromosome of claim 1.

34. A homogeneous population of *V. cholerae* cells, each of which comprises the chromosome of claim 1.

10 35. A live-cell vaccine comprising the cell of claim 32 in a pharmaceutically acceptable diluent suitable for oral administration.



15 36. The vaccine of claim 35, wherein said chromosome does not encode biologically active cholera toxin A subunit.

37. The vaccine of claim 36, wherein said chromosome does not encode biologically active IrgA.

38. The vaccine of claim 37, wherein said heterologous antigen is Shiga-like toxin B subunit.

20 39. A method of vaccinating an animal comprising orally administering to said animal the vaccine of claim 35.

40. The method of claim 39, wherein said animal is a human.



INTERNATIONAL SEARCH REPORT

Int'l application No.
PCT/US94/01780

C (Continued): DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	INFECTION AND IMMUNITY, Volume 58, No.1, issued January 1990, Goldberg et al., "Identification of an iron-regulated virulence determinant in <i>Vibrio cholerae</i> , using <i>TnphoA</i> mutants, pages 55-60, see entire document.	1-40
Y	NATURE, Volume 327, issued 11 JUNE 1987, Jacobs et al., "Introduction of foreign DNA into mycobacteria using a shuttle plasmid", pages 532-534, see entire document.	1-40

Form PCT/ISA/210 (continuation of second sheet)(July 1992)•